TimFGretenMD

Hematology • Bethesda, MD

Physician

Join to view full profile

Dr. Greten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Greten's full profile

Already have an account?

Office
Nci Building 10 Rm 12n226
10 Center Drive
Bethesda, MD 20892
Phone+1 240-760-6114

Education & Training

University of Kiel Faculty of MedicineClass of 1992

Certifications & Licensure

MD State Medical License 2011 - 2026

Clinical Trials

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma Start of enrollment: 2007 Feb 01
Completed
Phase 3
Sorafenib and TRC105 in Hepatocellular Cancer Start of enrollment: 2011 Feb 11
Completed
Phase 1, Phase 2
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer Start of enrollment: 2011 Mar 02
Recruiting
TRC105 for Liver Cancer That Has Not Responded to Sorafenib Start of enrollment: 2011 Jun 22
Completed
Phase 2
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Start of enrollment: 2017 Jun 14
Completed
Phase 2
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Start of enrollment: 2020 Aug 09
Completed
Phase 2
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) Start of enrollment: 2021 Dec 08
Recruiting
Phase 1
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). Start of enrollment: 2022 Feb 15
Terminated
Phase 2
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma Start of enrollment: 2021 Mar 10
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy.
Laetitia Saccenti, Nicole Varble, Tabea Borde, Andrew S Mikhail, Michael Kassin
La Radiologia Medica. 2024-12-10
Protocol for establishing liver tumors via ultrasound-guided intrahepatic injection prior partial hepatic resection in a mouse model.
Shadin Ghabra, Rajiv Trehan, Francisco Rodriguez-Matos, Chi Ma, Tim F Greten
STAR Protocols. 2024-10-22
A Paradoxical Tumor Antigen Specific Response in the Liver.
Rajiv Trehan, Xiao Bin Zhu, Patrick Huang, Xin Wang, Marlaine Soliman
Biorxiv. 2024-09-24

Press Mentions

Drugs for Advanced Breast Cancer Could Help Patients with Rare Cancer That Affects Bile DuctsOctober 23rd, 2024
Treatments Used for HER2-Positive Breast Cancers Could Help Patients with Rare Gastrointestinal CancerOctober 23rd, 2024
Roundtable Discussion: Has Interventional Oncology Established Itself as the Fourth Pillar of Oncology?October 24th, 2022
Join now to see all

Other Languages

German